POLARIX 5yr Update from Lymphoma ASH 2024

4 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
In this episode of the Oncology Brothers podcast, we wrap up our series on the highlights from ASH 2024, focusing specifically on key studies in lymphoma. Drs. Rahul & Rohit Gosain are joined by Dr. Pallawi Torka from Memorial Sloan Kettering Cancer Center, who provides valuable insights into several important trials.

We begin with the POLARIX study, which evaluates the use of polatuzumab in frontline diffuse large B-cell lymphoma (DLBCL). Dr. Torka discusses the study design, findings, and how she incorporates this treatment into her clinical practice, noting a modest but statistically significant improvement in progression-free survival (PFS) without a clear overall survival (OS) benefit.

Full Podcast: https://youtu.be/BctFfu_lFks

Main Channel: https://www.youtube.com/@UCjfxKlVho5xWH5ltufj4F4A

Follow us on social media:
•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers

Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology research and practice!
#OncologyBrothers #ASH2024 #Lymphoma #CancerResearch #podcast
Category
Oncology
Be the first to comment

Up Next